Early-onset colorectal cancer is reshaping how insurers assess and manage risk, prompting shifts in underwriting, product design, and wellness strategy. This article, from RGA's
New NHS-Galleri study results show that the trial did not meet its primary endpoint of a statistically significant reduction in combined Stage III and IV cancer diagnoses. Secondary findings were more encouraging, although they should be interpreted cautiously. For i...
Read More
Cancer is showing up earlier than many underwriting frameworks were built to expect. When RGA Vice President of Underwriting Research and Development Jackie Waas learned she had medullary thyroid cancer, the diagnosis became both personal and professional. In this ar...
Read MoreRGA produces a number of specialized publications featuring expert opinion and analysis. Explore our public collection or contact us for whitepapers, webinars, and other resources.
Explore the industry's premier medical underwriting publication.
Explore the ReFlections SeriesInvestigate product development trends and developments from around the world.
Explore the Product Trends Series
